Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC73225ROS-generating agent 1CAS: 2369030-41-9纯度: >99.00%
ROS-generating agent 1(化合物2c)共价修饰TrxR的Sec-498残基生成ROS。
- GC73272PARP-1-IN-3CAS: 2976342-33-1纯度: >99.00%
PARP-1-IN-3苯甲酰胺衍生物是一种强效的PARP-1抑制剂,PARP-1和PARP-2的IC50值分别为0.25 nM和2.34 nM。
- GC73274EGFR T790M/L858R-IN-2CAS: 2955607-40-4纯度: >99.00%
EGFR T790M/L858R-IN-2是一种有效的选择性EGFRT790M/L858R抑制剂,对EGFRT790M/L858R和EGFR WT的IC50值分别为3.5和1290 nM。
- GC73309Anti-melanoma agent 1CAS: 2418579-17-4纯度: >99.00%
Anti-melanoma agent 1(化合物5m)是一种抗黑色素瘤药物,可诱导细胞凋亡。
- GC73313PI3Kα-IN-9CAS: 2715287-67-3纯度: >99.00%
PI3Kα-IN-9(化合物27)是一种选择性、长效和口服活性的PI3Kα抑制剂,对PI3Kα、PI3Kγ、PI3Kδ和PI3Kβ的IC50值分别为4.4、128、146和153 nM。
- GC73355STAT3-SH2 domain inhibitor 1CAS: 2816059-41-1纯度: >98.50%
STAT3-SH2 domain inhibitor 1是STAT3(STAT3-SH2结构域)的强效Src同源2(SH2)结构域抑制剂,Kd值为1.57μM。
- GC73371Enpp/Carbonic anhydrase-IN-2CAS: 2883495-39-2纯度: >99.00%
Enpp/Carbonic anhydrase-IN-2是一种强效的Enpp和碳酸酐酶抑制剂,NPP1、NPP2、NPP3、CA-IX、CA-XII的IC50分别为1.13、1.07、0.74、0.33、0.68。
- GC73372(S)-SabutoclaxCAS: 1228178-73-1纯度: >98.00%
(S)-SabutoclaxS-BI-97C1是一种光学纯的棉酚衍生物,是抗凋亡B细胞淋巴瘤/白血病-2 Bcl-2家族蛋白的泛活性抑制剂。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC73225 | ROS-generating agent 1 | 2369030-41-9 | >99.00% | |
ROS-generating agent 1(化合物2c)共价修饰TrxR的Sec-498残基生成ROS。 | ||||
| GC73228 | MS78 | 3034773-00-4 | >99.00% | |
MS78是乙酰化靶向嵌合体(AceTAC),其乙酰化p53肿瘤抑制蛋白。 | ||||
| GC73232 | PRDX1-IN-1 | - | >98.00% | |
PRDX1-IN-1是PRDX1的选择性抑制剂,IC50值为0.164μM。 | ||||
| GC73234 | MY-673 | 2944459-96-3 | >98.00% | |
MY-673是抑制微管蛋白聚合的秋水仙素结合位点抑制剂(CBSI)。 | ||||
| GC73237 | BWA-522 | 3042820-12-9 | >99.00% | |
BWA-522是一种口服小分子蛋白靶向嵌合体(PROTACs),对AR-FL和AR-V7具有显著的降解作用。 | ||||
| GC73243 | Nrf2-IN-3 | 6325-13-9 | >99.00% | |
Nrf2-IN-3(化合物R16)是一种Nrf2抑制剂。 | ||||
| GC73268 | PH14 | - | >99.00% | |
PH14是PI3K/HDAC双抑制剂,对PI3Kα和HDAC3的IC50值分别为20.3 nM和24.5 nM。 | ||||
| GC73269 | ABBV-467 | 2287186-66-5 | >99.00% | |
ABBV-467是一种选择性MCL-1抑制剂(Ki: <0.01 nM)。 | ||||
| GC73272 | PARP-1-IN-3 | 2976342-33-1 | >99.00% | |
PARP-1-IN-3苯甲酰胺衍生物是一种强效的PARP-1抑制剂,PARP-1和PARP-2的IC50值分别为0.25 nM和2.34 nM。 | ||||
| GC73274 | EGFR T790M/L858R-IN-2 | 2955607-40-4 | >99.00% | |
EGFR T790M/L858R-IN-2是一种有效的选择性EGFRT790M/L858R抑制剂,对EGFRT790M/L858R和EGFR WT的IC50值分别为3.5和1290 nM。 | ||||
| GC73275 | PD-L1-IN-2 | 2894733-91-4 | >98.00% | |
PD-L1-IN-2是一种潜在的肿瘤免疫剂,通过抑制PD-L1。 | ||||
| GC73288 | CDK8-IN-13 | 918523-75-8 | >98.00% | |
CDK8-IN-13是一种强效、选择性且口服有效的CDK8抑制剂,IC 50 值为51.9nM。 | ||||
| GC73294 | F5446 | 2304465-89-0 | >99.00% | |
F5446(化合物1)是SUV39H1金属转移酶的选择性小分子抑制剂。 | ||||
| GC73309 | Anti-melanoma agent 1 | 2418579-17-4 | >99.00% | |
Anti-melanoma agent 1(化合物5m)是一种抗黑色素瘤药物,可诱导细胞凋亡。 | ||||
| GC73311 | STAT3-IN-13 | 2248552-86-3 | >99.00% | |
STAT3-IN-13(化合物6f)是一种有效的STAT3抑制剂。 | ||||
| GC73313 | PI3Kα-IN-9 | 2715287-67-3 | >99.00% | |
PI3Kα-IN-9(化合物27)是一种选择性、长效和口服活性的PI3Kα抑制剂,对PI3Kα、PI3Kγ、PI3Kδ和PI3Kβ的IC50值分别为4.4、128、146和153 nM。 | ||||
| GC73317 | ODN 1585 sodium | - | >93.00% | |
ODN 1585 sodium是IFN和TNFα产生的强效诱导剂。 | ||||
| GC73331 | BMS-37 | 1675202-20-6 | >98.00% | |
BMS-37是一种PD-1/PD-L1免疫检查点抑制剂。 | ||||
| GC73355 | STAT3-SH2 domain inhibitor 1 | 2816059-41-1 | >98.50% | |
STAT3-SH2 domain inhibitor 1是STAT3(STAT3-SH2结构域)的强效Src同源2(SH2)结构域抑制剂,Kd值为1.57μM。 | ||||
| GC73371 | Enpp/Carbonic anhydrase-IN-2 | 2883495-39-2 | >99.00% | |
Enpp/Carbonic anhydrase-IN-2是一种强效的Enpp和碳酸酐酶抑制剂,NPP1、NPP2、NPP3、CA-IX、CA-XII的IC50分别为1.13、1.07、0.74、0.33、0.68。 | ||||
| GC73372 | (S)-Sabutoclax | 1228178-73-1 | >98.00% | |
(S)-SabutoclaxS-BI-97C1是一种光学纯的棉酚衍生物,是抗凋亡B细胞淋巴瘤/白血病-2 Bcl-2家族蛋白的泛活性抑制剂。 | ||||
| GC73374 | TD1092 | - | >99.00% | |
TD1092是一种泛IAP降解剂,可降解cIAP1、cIAP2和XIAP。 | ||||
| GC73396 | PRMT6-IN-3 | 2890765-10-1 | >99.00% | |
PRMT6-IN-3(化合物25)是一种选择性PRMT6抑制剂,IC50值为192 nM。 | ||||
| GC73417 | CASP8-IN-1 | 1956368-39-0 | >98.00% | |
CASP8-IN-1(化合物63-R)是胱天蛋白酶8(CASP8)的选择性抑制剂,IC50为0.7μM。 | ||||
